Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Table 1 Baseline characteristics of 532 patients with non–small cell lung cancer (NSCLC)

Characteristic	No. of patients	Exon 19 deletion	Exon 21 L858R mutation	P value^b
Total	532	319	213
Age^a (years)				0.001
Median	59	57	61
Range	20–86	20–86	31–81
Sex				0.068
Male	210	136	74
Female	322	183	139
Smoking status				0.931
Never smoker	365	220	145
Ever smoker	145	88	57
Unknown	22	11	11
ECOG PS				0.202
0	117	58	59
1	292	178	114
2	26	15	11
3	8	4	4
Not evaluated	89	64	25
Clinical stage				0.572
IIIB	28	14	14
IV	495	301	194
Unknown	9	4	5
EGFR-TKI				0.270
Gefitinib	369	210	159
Erlotinib	82	56	26
Icotinib	56	34	22
Unknown	25	19	6
TKI line				0.004
Maintenance	11	1	10
Line 1	280	157	123
Line 2	173	118	55
Line ≥3	60	36	24
Unknown	8	7	1

ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
^aExcept for this value, other values are all presented as the number of patients
^bAnalyzed by using χ² test

ISSN: 2523-3548